Fibromyalgia – FDA approves Cyclobenzaprine

The FDA has approved cyclobenzaprine hydrochloride sublingual tablets, a first-in-class, non-opioid treatment for adults with fibromyalgia, a chronic pain syndrome that affects more than 10 million Americans, roughly 80% of whom are women. The medication, taken once-daily at bedtime, targets nonrestorative sleep, a root cause of pain, fatigue, and brain fog in fibromyalgia. It’s the Read more

Virtual reality for stroke rehabilitation

Virtual reality (VR) applications have emerged as a treatment approach in stroke rehabilitation. Different types of studies have been used from non‐immersive, non‐customised, interactive game‐based applications to immersive applications specifically designed for rehabilitation settings. Objectives Primary objective: to assess the effects of VR compared with an alternative intervention or no Read more

Glucagon-Like Peptide-1 – GLP1

Glucagon-Like Peptide-1 (GLP-1) is a natural  hormone secreted by the intestinal – L cells in response to food that enhances insulin secretion, suppresses glucagon rerelease, delays gastric emptying, acts on the brain to promote satiety.  GLP-1 plays a vital role in blood sugar control. It has been reported that GLP-1 Read more

Generative AI Chatbot for Mental Health Treatment -a RCT

BACKGROUND Generative artificial intelligence (Gen-AI) chatbots hold promise for building highly personalized, effective mental health treatments at scale, while also addressing user engagement and retention issues common among digital therapeutics. METHODS A RCT with (N=210) with clinically significant symptoms of major depressive disorder (MDD), generalized anxiety disorder (GAD), or at Read more

Effectiveness and safety of drugs for obesity

American Gastroenterological Association (AGA) guidelines are the first to make priority recommendations for antiobesity medication selection on the basis of available evidence from individual agent trials explicitly recommending the use of (a) semaglutide 2.4 mg because of the magnitude of clinical benefit (b) next prioritize liraglutide 3.0 mg, followed by Read more